What Is the GLOW Stack?

The GLOW Stack is a three-peptide research formulation combining BPC-157 (CAS 137525-51-0), TB-500 (CAS 77591-33-4), and GHK-Cu (CAS 89030-95-5). Building on the dual-mechanism tissue repair framework of the BPC-157 + TB-500 Co-Formulation (BPC-157 + TB-500), the GLOW Stack adds GHK-Cu—a copper-binding tripeptide that engages distinct collagen synthesis, antioxidant defense, and growth factor modulation pathways—to create a three-component formulation studied for broader engagement of tissue regeneration biology in research contexts. Each compound addresses a different cellular and molecular target: BPC-157 modulates growth factor receptor signaling and angiogenesis, TB-500 governs actin cytoskeletal dynamics and cell migration, and GHK-Cu drives copper-dependent collagen biosynthesis, antioxidant defense, and TGF-β pathway modulation. The GLOW Stack is used exclusively in laboratory research by qualified professionals.

Stack Composition

GHK-Cu: Research Profile

GHK-Cu (copper peptide GHK; CAS 89030-95-5) is the copper(II) complex of the tripeptide Glycine-Histidine-Lysine (GHK), a sequence first identified as an endogenous plasma constituent and later characterized as a potent regulator of tissue repair, collagen biosynthesis, and antioxidant defense. The tripeptide coordinates Cu²⁺ through the imidazole nitrogen of histidine and the alpha-amino nitrogen of glycine in a square-planar coordination geometry, forming a stable complex with high copper affinity (log K ~16). GHK-Cu functions as an endogenous copper chaperone, facilitating copper delivery to cuproenzymes including lysyl oxidase (LOX)—the enzyme required for collagen and elastin crosslinking—and copper-zinc superoxide dismutase (Cu/Zn-SOD), which catalyzes superoxide radical dismutation. Research has documented that GHK-Cu stimulates fibroblast collagen type I and III synthesis, promotes wound contraction, modulates TGF-β1 and TGF-β2 isoform expression, and activates matrix metalloproteinase (MMP) activity to facilitate remodeling of damaged extracellular matrix. The compound also activates the Nrf2 antioxidant response element pathway, upregulating cytoprotective genes including heme oxygenase-1 (HO-1) and glutamate-cysteine ligase (GCL). GHK-Cu has been studied across skin repair, wound healing, hair follicle research, and nerve regeneration model systems.

BPC-157 and TB-500: Research Profiles

BPC-157 (CAS 137525-51-0; 15-AA synthetic gastric protein-derived peptide; MW 1419.55 g/mol) is studied for its modulation of VEGF-driven angiogenesis, FAK-paxillin pathway activation, and cytoprotective properties across multiple tissue types including tendon, muscle, gastrointestinal mucosa, and bone in preclinical research models. TB-500 (CAS 77591-33-4; 43-AA thymosin-β4 analogue; MW 4963.4 g/mol) is the synthetic form of thymosin beta-4, the primary G-actin sequestering protein in non-muscle cells. TB-500 research focuses on actin dynamics regulation through the LKKTETQ pharmacophore, cell migration facilitation, and anti-fibrotic signaling via its N-terminal Ac-SDKP tetrapeptide. Together, BPC-157 and TB-500 constitute the BPC-157 + TB-500 Co-Formulation core, which is extended by GHK-Cu in the GLOW formulation.

Research Rationale

The GLOW Stack’s three-component research rationale rests on the mechanistic complementarity of each compound at different levels of tissue repair biology. BPC-157 addresses the vascular and growth factor signaling environment—upregulating VEGF to drive new vessel formation and activating FAK-paxillin to enhance fibroblast adhesion, providing the vascular and chemotactic infrastructure for repair. TB-500 addresses the cytoskeletal level—sequestering G-actin to regulate the dynamic equilibrium between polymerized and free actin, thereby controlling whether repair-competent cells can migrate directionally toward wound sites and form the organized cellular architecture needed for tissue reconstruction. GHK-Cu addresses the extracellular matrix level—delivering copper to LOX for collagen crosslinking, stimulating collagen I and III synthesis, modulating MMP activity for matrix remodeling, and activating Nrf2-dependent antioxidant genes that protect newly synthesized matrix from oxidative degradation. Research programs using the GLOW Stack examine whether simultaneous engagement of these three non-overlapping biological levels produces qualitatively or quantitatively different outcomes than any two-compound combination in tissue repair research model systems.

Research Areas

What does GLOW Stack research examine regarding collagen and extracellular matrix?

GHK-Cu’s collagen-stimulating activity adds a distinct extracellular matrix dimension to the GLOW Stack’s research profile beyond what BPC-157 and TB-500 alone provide. Research has documented that GHK-Cu increases fibroblast collagen type I and III mRNA expression, stimulates procollagen secretion, and activates LOX-mediated collagen crosslinking by delivering copper to the LOX catalytic center. Simultaneously, GHK-Cu modulates MMP-1 (collagenase) and MMP-2 (gelatinase) activity, promoting controlled matrix remodeling rather than net matrix accumulation. The GLOW Stack research context examines whether this GHK-Cu-driven collagen matrix regulation, combined with the vascular environment established by BPC-157 and the cell migration capacity enabled by TB-500, produces a research model system where all three phases of tissue repair—revascularization, cell recruitment, and matrix deposition—are simultaneously engaged by pharmacologically distinct compounds.

How does GHK-Cu contribute to antioxidant research in the GLOW Stack context?

Oxidative stress is a key feature of acute tissue injury: reactive oxygen species (ROS) generated by neutrophil respiratory burst, ischemia-reperfusion, and mitochondrial dysfunction can degrade newly deposited collagen, damage cell membranes, and impair vascular endothelial function at repair sites. GHK-Cu contributes antioxidant activity to the GLOW Stack through two complementary mechanisms: direct copper delivery to Cu/Zn-SOD, enhancing enzymatic superoxide dismutation capacity, and Nrf2 pathway activation, which drives transcription of cytoprotective antioxidant genes including HO-1, NQO1, and GCL. This antioxidant component is research-relevant in the GLOW Stack context because it may protect the vascular architecture promoted by BPC-157 and the migrating repair cells facilitated by TB-500 from oxidative damage at active repair sites. Research examining the combination explores whether GHK-Cu’s antioxidant contributions improve the durability of repair processes engaged by the other two stack components.

What skin and dermal research applications involve the GLOW Stack?

GHK-Cu has an established research profile in skin biology—modulating dermal fibroblast activity, collagen and glycosaminoglycan synthesis, and wound contraction in cutaneous repair models. BPC-157 has been studied in skin wound healing for its pro-angiogenic and fibroblast-activating properties, and TB-500 has been examined for keratinocyte and fibroblast migration in cutaneous wound closure research. The GLOW Stack combination has research applications in dermal tissue contexts where all three aspects of skin repair biology—vascularization, cell migration, and matrix synthesis—are studied simultaneously. Research examining the GLOW Stack in skin repair model systems aims to characterize whether GHK-Cu’s matrix and antioxidant contributions measurably complement the cellular and vascular effects of BPC-157 and TB-500 in research wound models.

Frequently Asked Questions

What is the GLOW Stack?

The GLOW Stack is a three-peptide research formulation combining BPC-157 (CAS 137525-51-0), TB-500 (CAS 77591-33-4), and GHK-Cu (CAS 89030-95-5). It extends the BPC-157 + TB-500 Co-Formulation (BPC-157 + TB-500) by adding GHK-Cu, a copper-binding tripeptide that stimulates collagen biosynthesis, activates Nrf2 antioxidant pathways, and delivers copper to crosslinking and antioxidant enzymes. The three components engage vascular signaling, cytoskeletal dynamics, and extracellular matrix biology through mechanistically distinct pathways. For laboratory research use only.

What are the CAS numbers for all GLOW Stack components?

The GLOW Stack contains three research compounds: BPC-157 (CAS 137525-51-0; MW 1419.55 g/mol; 15-amino acid synthetic peptide), TB-500 (CAS 77591-33-4; MW 4963.4 g/mol; 43-amino acid thymosin-β4 analogue), and GHK-Cu (CAS 89030-95-5; ~396.9 g/mol Cu complex; Gly-His-Lys copper(II) complex). Each compound has an independent published research base in preclinical tissue repair and repair-related biology model systems.

What does GHK-Cu add to the BPC-157 and TB-500 combination?

GHK-Cu (CAS 89030-95-5) adds three distinct research-relevant activities to the BPC-157/TB-500 core: (1) copper-dependent collagen synthesis stimulation via LOX activation and fibroblast type I/III collagen upregulation; (2) MMP-mediated extracellular matrix remodeling modulation for controlled matrix turnover rather than fibrotic accumulation; and (3) Nrf2 pathway-driven antioxidant gene expression including HO-1 and GCL, protecting repair site biology from oxidative damage. These contributions address the extracellular matrix biology dimension not covered by BPC-157’s vascular signaling or TB-500’s cytoskeletal dynamics activity.

What is the coordination chemistry of GHK-Cu?

GHK-Cu is the Cu²⁺ complex of the tripeptide Gly-His-Lys (GHK; CAS 89030-95-5). Copper(II) is coordinated in a square-planar geometry involving the alpha-amino nitrogen of glycine, the deprotonated amide nitrogen of the Gly-His peptide bond, and the imidazole nitrogen of histidine—a coordination mode termed the ATCUN (amino terminal copper and nickel) motif characteristic of peptides with N-terminal Xaa-His sequences. The resulting complex has high copper binding affinity (stability constant log K ~16) and functions as an endogenous copper chaperone, delivering Cu²⁺ to cuproenzymes including lysyl oxidase and Cu/Zn-SOD. CAS 89030-95-5 specifically denotes the copper complex form.

How does the GLOW Stack differ from the BPC-157 + TB-500 Co-Formulation?

The BPC-157 + TB-500 Co-Formulation contains BPC-157 (CAS 137525-51-0) and TB-500 (CAS 77591-33-4). The GLOW Stack adds GHK-Cu (CAS 89030-95-5) as a third component, extending the formulation to include copper-dependent collagen synthesis, Nrf2 antioxidant pathway activation, and MMP-mediated matrix remodeling alongside the angiogenic/growth factor (BPC-157) and cytoskeletal dynamics (TB-500) contributions of the base stack. The KLOW Stack is a separate four-peptide formulation containing BPC-157, GHK-Cu, KPV, and Ac-SDKP.

What is the Nrf2 pathway and why is it relevant to GHK-Cu research?

Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that responds to oxidative and electrophilic stress by translocating to the nucleus and activating antioxidant response element (ARE)-driven gene transcription. Nrf2-target genes include heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase (GCL), and thioredoxin reductase—collectively increasing the cell’s capacity to neutralize reactive oxygen species and repair oxidative damage. Research has shown GHK-Cu activates Nrf2 signaling, with downstream increases in HO-1 and GCL expression in fibroblast and epithelial research models. In the GLOW Stack context, this Nrf2 activation provides a cytoprotective antioxidant dimension that may protect the vascular and cellular repair processes engaged by BPC-157 and TB-500 from oxidative disruption at injury sites in research model systems.

What is the role of lysyl oxidase (LOX) in GHK-Cu research?

Lysyl oxidase (LOX) is a copper-dependent amine oxidase that catalyzes the oxidative deamination of lysine and hydroxylysine residues in collagen and elastin, generating reactive aldehyde groups that spontaneously condense to form covalent crosslinks—the primary mechanism for collagen fibril mechanical strength. LOX requires copper(II) in its catalytic center for activity; copper deficiency impairs LOX function and reduces the mechanical integrity of newly deposited collagen. Research on GHK-Cu examines whether the complex’s copper chaperone activity enhances LOX-mediated collagen crosslinking in fibroblast and tissue repair model systems, and whether GHK-Cu-driven collagen crosslinking quality differs measurably from collagen deposited under copper-limited conditions in preclinical research wound models.

Is the GLOW Stack related to the KLOW Stack?

Yes. Both are multi-peptide research formulations that share BPC-157 and GHK-Cu. The GLOW Stack contains BPC-157 (CAS 137525-51-0), TB-500 (CAS 77591-33-4), and GHK-Cu (CAS 89030-95-5). The KLOW Stack is a separate four-peptide formulation containing BPC-157, GHK-Cu, KPV (CAS 67727-97-3), and Ac-SDKP (CAS 64338-12-5); it uses the thymosin beta-4-derived tetrapeptide Ac-SDKP in place of full-length TB-500 and adds the anti-inflammatory tripeptide KPV. Both formulations are used in laboratory research to evaluate multi-mechanism tissue repair and anti-inflammatory pharmacology.

Published Research

The following peer-reviewed publications have examined BPC-157, TB-500 (thymosin beta-4), GHK-Cu, and related tissue repair and copper peptide research. These citations are provided for scientific reference and do not constitute endorsement of any application outside registered research programs.

• Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. PMID 21548867
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair experimentally insulted tissues. Trends Mol Med. 2005;11(9):421–429. PMID 16099219
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:151479. PMID 25143954
• Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–345. PMID 19500118
• Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. PMID 17108969
• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. PMID 29987191

Research Use Only Disclaimer

The GLOW Stack (BPC-157, CAS 137525-51-0; TB-500, CAS 77591-33-4; GHK-Cu, CAS 89030-95-5) is intended for laboratory research purposes by qualified professionals only. Not for human, animal, diagnostic, or therapeutic use. These compounds have not been evaluated by the FDA for clinical application, are not manufactured to pharmaceutical standards, and all applicable local, state, and federal regulations governing research compounds apply.